A recent study published in the New England Journal of Medicine has shown that a high-dose recombinant influenza vaccine is more effective than a standard-dose vaccine in adults aged 50 to 64.
The study compared the effectiveness of recombinant vaccines to standard-dose vaccines in preventing influenza-related outcomes in adults under 65 during the 2018 to 2019 and 2019 to 2020 influenza seasons.
Key findings of the study include:
Participants aged 50 to 64 who received the recombinant vaccine had a 15.3% higher relative vaccine effectiveness in preventing confirmed influenza than those who received the standard-dose vaccine.
The relative vaccine effectiveness against influenza A in the same age group was 15.7%.
The recombinant vaccine did not show a significant advantage over standard-dose vaccines in preventing influenza-related hospitalization.
It’s important to note that the study was funded by Sanofi, the Flublok vaccine manufacturer, a high-dose recombinant influenza vaccine.
The results suggest that the high-dose recombinant vaccine may provide better protection against influenza in adults aged 50 to 64 than standard-dose vaccines.
Influenza vaccines are essential in preventing the spread of the flu virus and reducing the severity of illness.
The vaccine choice may vary depending on individual factors, and healthcare providers need to consider the most appropriate option for their patients based on age and other relevant factors.
Scientists find link between immune response and Long COVID and findings of Scientists find new way to restore sense of smell in people with long COVID.
If you care about COVID, please read studies about new evidence on rare blood clots after COVID-19 vaccination, and how diets could help manage post-COVID syndrome.
The research findings can be found in New England Journal of Medicine.
Copyright © 2023 Knowridge Science Report. All rights reserved.
